...but Q2 will be impacted by some negatives (low antigen test sales; lion’s share of Diagnostics’ restructuring costs). For the FY, management has spread a lot of optimism backed by the strong order book, which is a consequence of the company’s innovative portfolio. The Q1 figures of Healthineers were a mix set of figures and missing consensus (sales: -2.5%; adjusted EBIT: -2.4%). Our expectations were only just beaten (sales: +0.2%; EBITDA: +0.5%), which can be partly explained by lower than ....